Trial reportMalaria journal2006
Methylene blue for malaria in Africa: results from a dose-finding study in combination with chloroquine.
Trial report in Malaria journal, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 2 syntheses or guidelines pooled it, 121 citations in OpenAlex.
- Evaluating the safety of oral methylene blue during swallowing assessment: a systematic review.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2021Pooled it
- Efficacy and safety of methylene blue in the treatment of malaria: a systematic review.BMC medicine · 2018Pooled it
- Pharmacokinetics andAntimicrobial agents and chemotherapy · 2020Trial
- Trial
- High absolute bioavailability of methylene blue given as an aqueous oral formulation.European journal of clinical pharmacology · 2009Trial
- Strong gametocytocidal effect of methylene blue-based combination therapy against falciparum malaria: a randomised controlled trial.PloS one · 2009Trial
- Efficacy of amodiaquine in the treatment of uncomplicated falciparum malaria in young children of rural north-western Burkina Faso.Malaria journal · 2008Trial
- Trial
- Glutathione redox system as a therapeutic target for Plasmodium: Opportunities, Challenges, and future perspectives.Folia microbiologica · 2026Review
- Article
- Malaria therapeutics: are we close enough?Parasites & vectors · 2023Review
- Foreign body removal with the assistance of ultrasound guidance and methylene blue staining in children-a cohort study.International orthopaedics · 2022Article
- Anti-infective dyes in the time of COVID.Dyes and pigments : an international journal · 2021Review
- Methylene Blue-Based Nano and Microparticles: Fabrication and Applications in Photodynamic Therapy.Polymers · 2021Review
- Comparative Study Regarding the Properties of Methylene Blue and Proflavine and Their Optimal Concentrations for In Vitro and In Vivo Applications.Diagnostics (Basel, Switzerland) · 2020Review
- Nucleoside-lipid-based nanocarriers for methylene blue delivery: potential application as anti-malarial drug.RSC advances · 2019Article
- Differential activity of methylene blue against erythrocytic and hepatic stages of Plasmodium.Malaria journal · 2018Article
- Photoantimicrobials-are we afraid of the light?The Lancet. Infectious diseases · 2017Review
- Evaluating Cinchona bark and quinine for treating and preventing malaria.Journal of the Royal Society of Medicine · 2017Article
- Methylene blue-induced neuronal protective mechanism against hypoxia-reoxygenation stress.Neuroscience · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The development of safe, effective and affordable drug combinations against malaria in Africa is a public health priority. Methylene blue (MB) has a similar mode of action as chloroquine (CQ) and has moreover been shown to selectively inhibit the Plasmodium falciparum glutathione reductase. In 2004, an uncontrolled dose-finding study on the combination MB-CQ was performed in 435 young children with uncomplicated falciparum malaria in Burkina Faso (CQ monotherapy had a > 50% clinical failure rate in this area in 2003). Three serious adverse events (SAE) occurred of which one was probably attributable to the study medication. In the per protocol safety analysis, there were no dose specific effects. The overall clinical and parasitological failure rates by day 14 were 10% [95% CI (7.5%, 14.0%)] and 24% [95% CI (19.4%, 28.3%)], respectively. MB appears to have efficacy against malaria, but the combination of CQ-MB is clearly not effective in the treatment of malaria in Africa.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.